Semaglutide (GLP-1) Research Overview: From Receptor Pharmacology to Published Trials
Semaglutide is among the most studied peptides ever synthesized, with an unusually large published evidence base for a research peptide. It is therefore a well-characterized reference compound for metabolic research, and claims about what its literature shows are easy to check.
The molecule
Semaglutide is a 31-amino-acid analog of human GLP-1 (glucagon-like peptide-1) with three deliberate modifications: an Aib substitution at position 8 that blocks DPP-4 degradation, a C18 fatty-diacid chain that binds albumin, and a spacer that optimizes that binding. Together, these modifications extend GLP-1's natural half-life from minutes to roughly a week. That duration made once-weekly dosing possible in the clinical programs.
Receptor pharmacology
Semaglutide is a selective agonist of the GLP-1 receptor, a class-B GPCR expressed in pancreatic beta cells, hypothalamic and hindbrain neurons, and other tissues. Receptor activation raises cAMP, potentiates glucose-dependent insulin secretion, slows gastric emptying and acts centrally on appetite circuits. Because its activity is limited to one receptor, with no GIP or glucagon activity, semaglutide is the natural comparator when studying the newer dual and triple agonists.
The published clinical evidence
Two landmark programs define the human literature. The SUSTAIN trials focused on type 2 diabetes; the STEP program focused on obesity. STEP 1 reported a mean ~15% body-weight reduction over 68 weeks versus ~2.4% with placebo. Subsequent published work (SELECT) demonstrated cardiovascular outcome benefits in non-diabetic participants with obesity. These results are why GLP-1 biology is currently the most active area of metabolic research.
Current research directions
- Receptor signaling bias and desensitization in cell models
- Central appetite circuitry mapping in rodent models
- Comparative pharmacology against dual/triple incretin agonists
- Muscle-preservation co-therapies during weight loss (an active trial area)
Laboratory notes
Research-grade semaglutide is supplied lyophilized and requires standard handling: reconstitute gently in bacteriostatic water, refrigerate, protect from light. Its fatty-acid chain makes it more surface-active than small peptides. Shaking can cause foaming, creating a real degradation risk. Verify each batch against its COA; molecular weight is ~4114 Da by mass spec.
We stock independently tested GLP-1 semaglutide (10mg vials), alongside cagrilintide for amylin-pathway comparison work. For research use only — not for human or veterinary use.